Comparison between Global Surfaces IPO and Mankind Pharma IPO.
Global Surfaces IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Mankind Pharma IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Global Surfaces IPO is up to ₹154.98 Cr whereas the issue size of the Mankind Pharma IPO is up to ₹4,326.36 Cr. The final issue price of Global Surfaces IPO is ₹140.00 per share and of Mankind Pharma IPO is ₹1,080.00 per share.
| Global Surfaces IPO | Mankind Pharma IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹1 per share |
| Issue Price (Lower) | ₹133.00 per share | ₹1,026.00 per share |
| Issue Price (Upper) | ₹140.00 per share | ₹1,080.00 per share |
| Issue Price (Final) | ₹140.00 per share | ₹1,080.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ||
| Market Lot Size | 100 shares | 13 shares |
| Fresh Issue Size | 85,20,000 shares | 0 shares |
| Fresh Issue Size (Amount) | up to ₹119.28 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 25,50,000 shares | 4,00,58,844 shares |
| OFS Issue Size (Amount) | up to ₹35.70 Cr | up to ₹4,326.36 Cr |
| Issue Size Total | 1,10,70,000 shares | 4,00,58,844 shares |
| Issue Size Total (Amount) | up to ₹154.98 Cr | up to ₹4,326.36 Cr |
Global Surfaces IPO opens on Mar 13, 2023, while Mankind Pharma IPO opens on Apr 25, 2023. The closing date of Global Surfaces IPO and Mankind Pharma IPO is Mar 15, 2023, and Apr 27, 2023, respectively.
| Global Surfaces IPO | Mankind Pharma IPO | |
|---|---|---|
| Anchor Bid Date | Mar 10, 2023 | Apr 24, 2023 |
| Issue Open | Mar 13, 2023 | Apr 25, 2023 |
| Issue Close | Mar 15, 2023 | Apr 27, 2023 |
| Basis Of Allotment (Tentative) | Mar 20, 2023 | May 03, 2023 |
| Initiation of Refunds (Tentative) | Mar 21, 2023 | May 04, 2023 |
| Credit of Share (Tentative) | Mar 22, 2023 | May 05, 2023 |
| Listing date (Tentative) | Mar 23, 2023 | May 09, 2023 |
| Anchor Lockin End date 1 | Apr 19, 2023 | Jun 02, 2023 |
| Anchor Lockin End date 2 | Jun 18, 2023 | Aug 01, 2023 |
Global Surfaces IPO P/E ratio is 21.84, as compared to Mankind Pharma IPO P/E ratio of 32.5.
| Global Surfaces IPO | Mankind Pharma IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)
| Company Financials (Restated Consolidated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 99.35 | 79.00 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 76.50 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 21.84 | 32.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹593.35 Cr. | ₹43263.60 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 26.59 | 27.60% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 20.85 | 26.10% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.28 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹10.52 | ₹33.20 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 32.51 | 27.70% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Global Surfaces IPO Retail Individual Investors (RII) are offered 38,74,500 shares while in Mankind Pharma IPO retail investors are offered 38,74,500 shares. Qualified Institutional Buyers (QIB) are offered 22,14,000 shares in Global Surfaces IPO and 80,11,769 shares in Mankind Pharma IPO.
| Global Surfaces IPO | Mankind Pharma IPO | |
|---|---|---|
| Anchor Investor Reservation | 33,21,000 shares | 1,20,17,652 shares |
| Market Maker Reservation | ||
| QIB | 22,14,000 shares | 80,11,769 shares |
| NII | 16,60,500 shares | 60,08,827 shares |
| RII | 38,74,500 shares | 1,40,20,596 shares |
| Employee | ||
| Others | ||
| Total | 1,10,70,000 shares | 4,00,58,844 shares |
Global Surfaces IPO subscribed 12.21x in total, whereas Mankind Pharma IPO subscribed 15.32x.
| Global Surfaces IPO | Mankind Pharma IPO | |
|---|---|---|
| QIB (times) | 8.95x | 49.16x |
| NII (times) | 33.10x | 3.80x |
| Big NII (times) | 35.00x | 4.99x |
| Small NII (times) | 29.29x | 1.41x |
| RII (times) | 5.12x | 0.92x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 12.21x | 15.32x |
